KR920019336A - 소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물 - Google Patents

소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물 Download PDF

Info

Publication number
KR920019336A
KR920019336A KR1019920006554A KR920006554A KR920019336A KR 920019336 A KR920019336 A KR 920019336A KR 1019920006554 A KR1019920006554 A KR 1019920006554A KR 920006554 A KR920006554 A KR 920006554A KR 920019336 A KR920019336 A KR 920019336A
Authority
KR
South Korea
Prior art keywords
group
mucoadhesive
gut
matrix
fatty acid
Prior art date
Application number
KR1019920006554A
Other languages
English (en)
Other versions
KR100217165B1 (ko
Inventor
요꼬 아끼야마
나오끼 나가하라
신 이찌로 히라이
Original Assignee
모리따 가쓰라
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모리따 가쓰라, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 모리따 가쓰라
Publication of KR920019336A publication Critical patent/KR920019336A/ko
Application granted granted Critical
Publication of KR100217165B1 publication Critical patent/KR100217165B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (35)

  1. 폴리글리세롤 지방산 에스테르 또는 지질 및 약효성분을 함유하는 매트릭스 입자의 적어도 표층 근방에서 물과 접촉하여 점성을 생성할 수 있는 점성물질이 분산되어 있는, 상온에서 고체인 소화관 점막 부착성 매트릭스.
  2. 제1항에 있어서, 상기 점성물질이 카르복실기 또는 그의 염을 함유하는 중합체, 셀룰로스 에테르, 분자량 200,000이상의 폴리에틸렌글리콜 및 천연점성물질로 이루어진 군으로부터 선택된 적어도 하나인 소화관 점막 부착성 매트릭스.
  3. 제1항에 있어서, 상기 점성물질이 아크릴산 중합체/ 및 또는 그의 염인 소화관 점막 부착성 매트릭스.
  4. 제2항에 있어서, 카르복실기 또는 그의 염을 함유하는 중합체가 그들의 구성단량체로서 아클릴산으로부터 수득될 수 있는 아크릴산 중합체 또는 그의 염인 소화관 점막 부착성 매트릭스.
  5. 제4항에 있어서, 아클릴산중합체 또는 그의 염이 각각 58.0~63.0중량%의 카르복실기를 포함하며 200,000~6,00,000의 분라량을 갖는 소화관 점막 부착성 매트릭스.
  6. 제2항에 있어서, 상기 셀룰로스에테르가 카르복시메틸셀룰로스 나트륨, 히드록시프로필메틸셀룰로스, 메틸셀룰로스 및 결정 셀룰로스-카르복시메틸셀룰로스 나트륨인소화관 점막 부착성 매트릭스.
  7. 제2항에 있어서, 천연 점성 물질이 점액질, 한천, 젤라틴, 펙틴, 카라기난(carrageenan), 알긴산 나트륨, 로커스트 빔 검(locust beam gum), 크산탄 검 및 트라가칸트 검(tragacanth gum), 아라비아 검, 키토산, 풀루란(pullulan) 및 왁시스타치(waxistarch)인 소화관 점막 부착성 매트릭스.
  8. 제1항에 있어서, 상기 점성물질의 함유량이 상기 매트릭스 입자의 전중량에 대하여 0.005~95중량%인 소화관 점막 부착성 매트릭스.
  9. 제1항에 있어서, 상기 폴리글릴세롤 지방산 에스테르가 하기 식(I)로 표시되는 폴리글리세롤과 포화 또는 불포화 고급 지방산의 에스테르인 소화관 점막 부착성 매트릭스.
    〔식중 n은 중합도를 나타내며, 2이상의 정수이다.〕
  10. 제9항에 있어서, n이 2~50인 소화관 점막 부착성 매트릭스.
  11. 제9항에 있어서, 상기 지방산이 탄소수 8~40의 포화 또는 불포화 고급 지방산인 소화관 점막 부착성 매트릭스.
  12. 제1항에 있어서, 상기 폴리글리세롤 지방산 에스테르가 베헨산 헥사(테트라)글리세리드, 스테아린산 모노(테트라) 글리세리드 스테아린산 펜타(테트라)글리세리드, 스테아린산 펜타(헥사)글리세리드, 스테아린산 세스퀴(헥사)글리세리드, 스테아린산 모노(테카(글리세리드 도는 그들의 혼합물인 소화관 점막 부착성 매트릭스.
  13. 제1항에 있어서, 상기 폴리그릴세롤 지방산 에스테르가 1~22의 HLB(hydrophile-lipophile balance)를 갖는 점막 부착성 매트리스.
  14. 제1항에 있어서, 상기 폴리글리세롤 지방산 에스테르의 융점이 15-80℃인 소화관 점막 부착성 매트리스.
  15. 제1항에 있어서, 상기 지질의 융점이 40-120℃인 소화관 점막 부착성 매트릭스.
  16. 제1항에 있어서, 상기 지질이 C14~22의 포화 지방산 또는 그의 염, C16~22의 고급알콜, 지방산 글리세롤 에스테르, 오일류, 왁스류, 탄화수소 또는 인지질인 소화관 점막 부착성 매트릭스.
  17. 제1항에 있어서, 약효성분이 항궤양제 또는 위염 치료제인 소화관 점낙 부착성 매트릭스.
  18. 제1항에 있어서, 상기 약효성분이 하기식(Ⅱ)으로 표시되는 화합물 또는 약리학적으로 허용되는 염인 소화관 점막 부착성 매트릭스.
    〔식중, R1은 수소원자, 알킬기, 할로겐원자, 시아노기, 카르복시기, 알콕시, 카르보닐기, 알콕시카르보닐알킬기, 카르보모일기, 카르바모일알킬기, 히드록시기, 알콕시기, 히드록시알킬기, 트리플루오로메틸기, 아실기, 카릅바모일옥시기, 니트로기, 아실옥시기, 아릴기, 아릴옥시기, 알킬티오기, 또는 알킬술피닐기를 나타내고; R2는 수소원자, 알킬기, 아실기, 알콕시카르보닐기, 카르바모일기, 알킬카르바모일기, 디알킬카르바모일기, 알킬카르보닐메틸기, 알콕시카르보닐메틸기 또는 알킬술포닐기를 나타내고; R3및 R5는 동일 또는 상이하며, 각기 수소원자, 알킬기, 알콕시기 또는 알콕시 알콕시기를 나타내고; R4는 수소원자, 알킬기, 불소화되어 있어도 좋은 알콕시기, 알콕시 알콕시기, 불소화되어 있어도 좋은 알케닐옥시기 또는 불소화되어 있어도 좋은 알키닐옥시기를 나타내고 m은 0 내지 4의 정수를 나타낸다.〕
  19. 제18항에 있어서, 상기 식(Ⅱ)으로 표시되는 화합물의 R1, R2및 R5가 수소원자이고, R3이 수소원자 또는 메틸기인 소화관 점막부착성 매트릭스.
  20. 제18항에 있어서, 상기 식(Ⅱ)으로 표시되는 화합물의 R4가 불소화된 C1~4의 알콕시기인 소화관 점막 부착성 매트릭스.
  21. 제18항에 있어서, 상기 식(Ⅱ)으로 표시되는 화합물의 R1이 5위치에서 치환된 수소원자, 불소원자, 메톡시기 또는 트리플루오로메틸기이고; R2가 수소원자이고; R3이 수소원자 또는 메틸기이고; R4가 불소화되어 있어도 좋은 C1~4알콕시기, 2-프로페닐옥시기 또는 알릴기이고; R5가 수소원자 또는 메틸기이고, m=1인 소화관 점막 부착성 매트릭스.
  22. 제1항에 있어서, 산성 약호성분과 함께 물에 대하여 불용 또는 난용의 고체 염기를 함유하는 소화관 점막 부착성 매트리스.
  23. 제1항에 있어서, 염기성 약효성분과 함께 장용성 중합체를 함유하는 소화관 점막 부착성 매트릭스.
  24. 제1항에 있어서, 매트릭스 입자에 있어서의 폴리글리세롤 지방산 에스테르 및/또는 상기 지질의 함유량이 상기 약효성분의 1중량부에 대하여 0.001~10000중량부인 소화관 점막 부착성 매트리스.
  25. 제1항에 있어서, 상기 식(I)으로 표시되는 폴리글리세롤(n은 2~50)과 탄소수 8 내지 40의 포화 또는 불포화 고급 지방산의 에스테르 및/또는 상기 지질과, 상기 약효성분과, 상기 점성물질을 함유하는 매트릭스 입자중에서, 상기 폴리그릴세롤 지방산 에스테르 및/또는 지질의 함유량이 약효성 분량 1중량부에 대하여 0.001~10,0000중량부이고, 상기 점성물질이 아크릴 산 중합체 및/또는 그의 염을 소화관 점막 부착성 매트리스.
  26. 제1항에 있어서, 상기 매트릭스의 융점이 30~120℃인 소화관 점막 부착성 매트릭스.
  27. 폴리글리세롤 지방산 에스테르 또는 지질 및 약효성분을 포함하는 매트릭스 입자로, 상기 입자는 물과의 접촉으로 점성을 생성하는 점성물질을 포함하는 코우팅 조성물로부터 형성되는 피복층을 갖는, 상온에서 고체인 소화관 점막 부착성 매트리스.
  28. 제27항에 있어서, 상기 피복층이 폴리글리세롤 지방산 에스테르, 지질, 장용성 중합체 및 수불용성 중합체로 이루어진 군으로부터 선택된 적어도 하나의 성분을 함유하는 소화관 점막 부착성 매트릭스.
  29. 제27항에 있어서, 상기 피복층 중의 점성물징의 함유량이 피복층 전량을 기준으로 0.005~100중량%인 소화관 점막 매트릭스.
  30. 제27항에 있어서, 상기 매트릭스 입자를 기준으로 상기 코우팅 조성물의 피복량이 0.1~100중량%인 소화관 점막 부착성 매트릭스.
  31. (1)폴리글리세롤 지방산 에스테르 또는 지질과 약효성분을 함유하는 매트릭스 입자의 적어도 표층 근방에서 물과 접촉하여 점성을 생성시킬수 있는 점성물질이 분산되어 있는 상온에서 고체인 소화관 점막 부착성 매트릭스 또는 (2)폴리글리세롤 지방산 에스테르 또는 지질과 약효성분을 함유하는 매트릭스 입자가 물과의 접촉으로 점성을 생성시키는 점성물질을 함유하는 코우팅 조성물로 피복되어 있는 상온에서 고체인 소화관 점막 부착성 매트리스를 함유하는 고형약제.
  32. 제31항에 있어서, 고형 약재의 투약형태가 세립제, 과립제, 환제, 상기 세립제 또는 과립제를 압축 성형한 정제 및 상기 세립제 또는 과립제를 캡슐에 충전하여 수득될 수 있는 캡슐제로 이루어진 군으로부터 선택된 고형약제.
  33. 적어도 물과 접촉하여 점성을 생성시키는 점성물질로 함유하는 코우팅 조성물.
  34. 제33항에 있어서, 폴리글리세롤 지방산 에스테트, 지질, 장용성 중합체 및 수불용성 중합체로 이루어진 군으로부터 선택된 적어도 하나의 성분을 함유하는 코우팅 조성물.
  35. 제33항에 있어서, 비휘발 물질을 기준으로, 상기 점성물질을 0.005~100중량%함유하는 코우팅 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920006554A 1991-04-19 1992-04-18 소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물 KR100217165B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP91-116745 1991-04-19
JP11674591 1991-04-19
JP91-225155 1991-08-09
JP22515591 1991-08-09

Publications (2)

Publication Number Publication Date
KR920019336A true KR920019336A (ko) 1992-11-19
KR100217165B1 KR100217165B1 (ko) 1999-09-01

Family

ID=26455015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920006554A KR100217165B1 (ko) 1991-04-19 1992-04-18 소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물

Country Status (12)

Country Link
US (4) US5576025A (ko)
EP (1) EP0514008B1 (ko)
JP (4) JP3272029B2 (ko)
KR (1) KR100217165B1 (ko)
AT (1) ATE149348T1 (ko)
CA (1) CA2066384C (ko)
DE (1) DE69217711T2 (ko)
DK (1) DK0514008T3 (ko)
ES (1) ES2098447T3 (ko)
GR (1) GR3023383T3 (ko)
SG (1) SG50480A1 (ko)
TW (1) TW209174B (ko)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
TW282403B (ko) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
ATE192932T1 (de) 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
GB9505032D0 (en) * 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19600324A1 (de) 1996-01-08 1997-07-10 Basf Ag Granulate für kosmetische und pharmazeutische Zubereitungen
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
AU717764B2 (en) * 1996-05-02 2000-03-30 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
CN1251035A (zh) 1997-03-25 2000-04-19 武田药品工业株式会社 胃肠粘膜粘附性药物组合物
AU6422798A (en) * 1997-03-25 1998-10-20 Takeda Chemical Industries Ltd. Stabilized urease inhibitor
ATE285226T1 (de) * 1997-08-11 2005-01-15 Alza Corp Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CN1268060A (zh) * 1997-08-27 2000-09-27 武田药品工业株式会社 缓释口服制剂
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
CN1293576A (zh) 1998-03-20 2001-05-02 兴和株式会社 胃和/或十二指肠粘附性药物组合物
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
MXPA01012659A (es) 1999-06-07 2003-09-04 Altana Pharma Ag Nueva forma de administracion y preparacion que comprende un compuesto activo labil acido.
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
JP4659316B2 (ja) * 1999-08-09 2011-03-30 大日本住友製薬株式会社 キトサン粉末含有固形製剤およびその製造方法
JP2001048809A (ja) * 1999-08-10 2001-02-20 Dainippon Pharmaceut Co Ltd ポリグリセリンベヘニン酸エステル含有徐放性坐剤
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
US6663883B1 (en) 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
CN1312080A (zh) * 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
JP4779192B2 (ja) * 2000-09-13 2011-09-28 大正製薬株式会社 溶出制御された製剤用粒子
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP2085087A1 (en) * 2001-06-11 2009-08-05 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
ES2187380A1 (es) * 2001-11-16 2003-06-01 Sanchez Juan Balufo Mejoras introducidas en productos destinados al consumo humano o animal.
AU2003203034A1 (en) * 2002-01-14 2003-07-30 Vertex Pharmaceuticals Incorporated Mucin immobilized chromatography
CA2472449C (en) * 2002-01-16 2010-03-09 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US7846478B2 (en) * 2002-01-31 2010-12-07 Henkel Ag & Co. Kgaa Bioadhesive composition
US8728510B1 (en) * 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US8623412B2 (en) 2002-09-23 2014-01-07 Elan Pharma International Limited Abuse-resistant pharmaceutical compositions
KR20050065550A (ko) * 2002-09-26 2005-06-29 아스텔라스세이야쿠 가부시키가이샤 약물 흡수성 개선제
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
CA2520813C (en) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
JPWO2005020960A1 (ja) * 2003-08-29 2007-11-01 佐藤製薬株式会社 直腸投与用製剤
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
BRPI0510310A (pt) * 2004-04-28 2007-10-16 Procarrier Inc formulação oral para aplicação de drogas fracamente absorvidas
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
EP1750674A4 (en) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp MICROPARTICLES FOR THE ORAL LEVY
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004036437A1 (de) * 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
DE102004059792A1 (de) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
JP4787503B2 (ja) * 2005-01-12 2011-10-05 京セラケミカル株式会社 固形製剤の製造方法
JP4787507B2 (ja) * 2005-01-24 2011-10-05 京セラケミカル株式会社 固形製剤及びその製造方法
CA2605792A1 (en) * 2005-04-25 2006-11-02 Teva Pharmaceuticals Usa, Inc. Extended release formulations
CA2521272A1 (en) * 2005-10-04 2007-04-04 Bernard Charles Sherman Capsules comprising topiramate
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
US8080094B2 (en) * 2007-01-22 2011-12-20 Y2 Ultra-Filter, Inc. Electrically stimulated air filter apparatus
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
CA2701605A1 (en) * 2007-10-03 2009-04-09 Asahi Breweries, Ltd. Granule, tablet and methods for producing the same
CN101918019B (zh) 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
EP2172203A1 (en) * 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
ES2908047T3 (es) 2009-03-27 2022-04-27 Intervet Int Bv Vacunas en micropartículas para la vacunación oral o nasal y el refuerzo de animales incluidos los peces
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
MY157343A (en) 2009-05-26 2016-05-31 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
FR2955258A1 (fr) * 2010-01-20 2011-07-22 Biopharmex Holding Ltd Composition injectable
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
RU2535869C2 (ru) 2010-01-28 2014-12-20 Эдванст Бионутришн Корпорейшн Сухая стекловидная композиция для стабилизации и защиты биологически активного материала и способ ее получения
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
KR101863920B1 (ko) 2010-08-13 2018-06-01 어드밴스드 바이오뉴트리션 코프. 생물학적 물질용 저장 안정화 건조 조성물
WO2012095746A2 (en) 2011-01-11 2012-07-19 Capsugel Belgium Nv New hard capsules
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US9636360B2 (en) 2012-09-18 2017-05-02 pH Science Holdings, Inc Method and composition for treating gastro-esophageal disorders
JP6285413B2 (ja) * 2013-02-25 2018-02-28 テルモ株式会社 多糖粉末およびこれを含む癒着防止材
RU2690672C2 (ru) 2014-08-11 2019-06-05 Перора Гмбх Способ обеспечения чувства сытости
ES2774978T3 (es) 2014-08-11 2020-07-23 Perora Gmbh Formulación que comprende partículas
US20180214411A1 (en) 2015-07-07 2018-08-02 Perora Gmbh Composition comprising satiety-inducing particles
CA2989510A1 (en) 2015-07-07 2017-01-12 Perora Gmbh Method of inducing satiety
WO2017019273A1 (en) 2015-07-29 2017-02-02 Advanced Bionutrition Corporation Stable dry probiotic compositions for special dietary uses
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
WO2018189584A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Pullulan capsules
WO2018189587A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Process for making pullulan
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
JP7260913B2 (ja) 2017-06-27 2023-04-19 株式会社バイオセレンタック 粘膜付着性経口製剤
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
CN113242738A (zh) * 2018-10-22 2021-08-10 Ioi油脂化学品有限责任公司 适用于压实为成形体的粉末材料的添加剂
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
US20220361552A1 (en) * 2019-12-10 2022-11-17 Tyler White Particles Containing a Lipid Matrix Core and Active Ingredient
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922339A (en) * 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
CH627449A5 (de) * 1977-03-25 1982-01-15 Hoffmann La Roche Verfahren zur herstellung von mikrokristallinem vitamin a-acetat, sowie von trockenen, frei-fliessenden praeparaten, in welchen vitamin a-acetat in mikrokristalliner form vorliegt.
JPS6042766B2 (ja) 1978-12-09 1985-09-25 日本化薬株式会社 基剤
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
FR2485370A1 (fr) * 1980-06-30 1981-12-31 Commissariat Energie Atomique Support inerte en copolymere reticule, son procede de preparation et son utilisation pour la realisation de medicaments retard
JPS6029682B2 (ja) 1980-07-11 1985-07-12 山之内製薬株式会社 苦味のない製剤用組成物およびその製造法
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS61148115A (ja) 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
JPS63101332A (ja) 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
DE3702029A1 (de) * 1987-01-24 1988-08-04 Basf Ag Waessriges oder pulverfoermiges, wasserdispergierbares praeparat eines in wasser schwerloeslichen pharmazeutischen wirkstoffs und verfahren zu seiner herstellung
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP2526965B2 (ja) 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
WO1989010117A1 (en) * 1988-04-19 1989-11-02 Southwest Research Institute Controlled release of active ingredients from capsules having a salt sensitive shell material
JP2759972B2 (ja) 1988-08-05 1998-05-28 富士通株式会社 セグメント顕示処理方法
NZ231281A (en) 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
JPH02193914A (ja) 1989-01-23 1990-07-31 Sumitomo Pharmaceut Co Ltd マトリックス型持続性製剤
ES2066120T3 (es) * 1989-02-10 1995-03-01 Takeda Chemical Industries Ltd Uso de derivados de bencimidazol como agentes antibacterianos.
JPH0720865B2 (ja) 1989-02-10 1995-03-08 武田薬品工業株式会社 抗菌剤
JPH0338247A (ja) 1989-07-06 1991-02-19 Nippon Kasei Kk 脱臭剤
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Also Published As

Publication number Publication date
JP2001354550A (ja) 2001-12-25
GR3023383T3 (en) 1997-08-29
EP0514008B1 (en) 1997-03-05
DK0514008T3 (da) 1997-05-12
ATE149348T1 (de) 1997-03-15
TW209174B (ko) 1993-07-11
DE69217711T2 (de) 1997-07-17
US20020142041A1 (en) 2002-10-03
CA2066384C (en) 2007-04-03
JPH05132416A (ja) 1993-05-28
JP3272029B2 (ja) 2002-04-08
JP4084000B2 (ja) 2008-04-30
CA2066384A1 (en) 1992-10-20
US6368635B1 (en) 2002-04-09
JP2001354593A (ja) 2001-12-25
EP0514008A1 (en) 1992-11-19
SG50480A1 (en) 1998-07-20
US5576025A (en) 1996-11-19
DE69217711D1 (de) 1997-04-10
KR100217165B1 (ko) 1999-09-01
ES2098447T3 (es) 1997-05-01
US5731006A (en) 1998-03-24
JP2007246547A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
KR920019336A (ko) 소화관 점막 부착성 매트릭스, 약제제 및 코우팅 조성물
FI98886C (fi) Menetelmä antasidivalmisteiden valmistamiseksi, joilla on pidennetty viipymisaika mahalaukussa
US5635520A (en) Anti-ulcer compositions suitable for rectal administration
KR100510356B1 (ko) 저장 안정성이 개선된 피복제 및 결합제를 포함하는 약제학적 제형 및 이의 제조방법
US9192582B2 (en) Gastric reflux resistant dosage forms
CA2664669A1 (en) A method of administering a film product containing a drug
KR870700344A (ko) 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도
EP2793867A2 (en) Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
KR20000076329A (ko) 위장 점막 부착성 약제 조성물
IL173110A (en) Semi-solid formulations for the oral administration of taxoids
ES2624003T3 (es) Películas de pH modulado para el suministro de principios activos
CA2452056A1 (en) Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
SE462779B (sv) Farmaceutisk komposition innehaallande n-acetylcystein i en kaerna belagd med hydroxipropylmetylcellulosaftalat
JP7323608B2 (ja) スマート放出のための非注射用ヒドロゲル製剤
CN1044591A (zh) 一种水分散二甲苯氧庚酸组合物的制备方法
Zaman et al. Gastrointestinal mucosa: the target site of mucoadhesive microspheres, a review
WO1999007341A1 (en) Compositions for nasal administration
JP4287948B2 (ja) 消化管粘膜付着性抗ヘリコバクター・ピロリ組成物
Bhattacharya et al. Entrapment of bioactive organosulfur allicin from garlic in polyoxyethylene based micelle carrier system for enhanced shelf-life: in vitro release kinetics and in silico analysis
CN112020370A (zh) 制剂
WO1999010010A1 (fr) Preparation orale a liberation prolongee
AKILADEVI et al. A comprehensive review of floating microspheres.
TWI624270B (zh) 藥物組合物
US20060013864A1 (en) Transmucosal pharmacuetical administration form
TH181888B (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030523

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee